Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
CASE SERIES
Year : 2022  |  Volume : 49  |  Issue : 1  |  Page : 76-80

Clinicopathological spectrum of gastrointestinal stromal tumors: A case series


1 Department of Pathology, Thanjavur Medical College and Hospital, Thanjavur, Tamil Nadu, India
2 Department of Surgical Gastroenterology, Thanjavur Medical College and Hospital, Thanjavur, Tamil Nadu, India
3 Department of Surgical Oncology, MR Hospitals, Thanjavur, Tamil Nadu, India

Correspondence Address:
Padmanaban Krishnan Govindaraman
Department of Pathology, Thanjavur Medical College Hospital, Thanjavur, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jss.jss_96_21

Rights and Permissions

Gastrointestinal stromal tumor (GIST) is the most common primary mesenchymal neoplasm of the gastrointestinal tract, and they are potentially malignant tumors with varied biological behavior. The objective of this study was to investigate the clinicopathological characteristics and prognostic factors of GISTs in our institution. Medical records of nine cases of GISTs diagnosed during January 2018 to March 2021 were reviewed. Details of patient demographics, clinical presentation, treatment details, and gross and histopathological features were noted. GISTs were commonly seen in stomach in 50–60-year age group with slight male preponderance. Abdominal pain was the most common symptom. Other sites encountered were colon, mesentery, peritoneum, and omentum. Most of the gastric GISTs were in low-risk group. Mean size of the tumor was 9.3 cm. Spindle cell type was the most common histological pattern with diffuse hypercellularity subtype. All cases were positive for CD117 (c-kit). One case was inoperable due to dissemination in abdominal cavity, surgery was done in all other cases, and imatinib therapy was given for high-risk cases postoperatively. GIST is uncommon with diverse clinical presentation. CD117 is a very sensitive marker for making a diagnosis of GIST. Successful management of GISTs requires complete surgical resection and adjuvant imatinib therapy for intermediate- and high-risk patient.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed150    
    Printed8    
    Emailed0    
    PDF Downloaded15    
    Comments [Add]    

Recommend this journal